Novartis Slovakia’s Post

To mark Lung Cancer Awareness Month, we are pleased to publish five new factsheets that highlight the essential role of targeted low-dose computed tomography (LDCT) screening for lung cancer in improving outcomes and reducing healthcare costs. Lung cancer imposes the highest cancer-related cost on health systems across the world, and accounts for one fifth of the 10 million deaths from cancer every year. The lack of clear symptoms in its earlier stages means lung cancer often remains undetected until it is more advanced, when treatment options are more limited and survival rates are much lower. LDCT screening represents a major opportunity for improving outcomes for people at risk of lung cancer. The factsheets are evidence-driven and bring together a wealth of clinical evidence, implementation research and expert insights from members of the Network. We hope they can equip policymakers and patient advocates with the information they need to make effective change in how we detect lung cancer. Read and download the factsheets here: https://lnkd.in/etfEEp6y

🌟 Biocon Foundation's OCTF Guidelines Recognized Among Global Clinical Standards in Cancers Journal! 🌟 🔬 Interesting News! The Consensus Guidelines for the Management of Head and Neck Cancer (HNC), crafted by the Oral Cancer Task Force (OCTF) with the unwavering support of Biocon Foundation, have achieved a remarkable feat! 🎉 📚 Featured among only 13 elite global clinical practice standards in the esteemed Cancers journal, these guidelines stand tall alongside renowned counterparts from the U.S., Europe, Canada, Japan, and the National Comprehensive Cancer Network. 🌐 🤝 Initiated in 2018, the OCTF, comprising top oncologists from India, aims to combat oral cancer through innovative strategies. With India-specific guidelines launched in 2020 and updated in 2023, these efforts signify a significant milestone in battling this prevalent disease. 💪 🇮🇳 With India facing the brunt of HNC cases, these guidelines are tailored to address local demographics, resources, and practices. The Biocon Foundation's commitment to downsize oral cancer, evident since 2011 through community screenings, is further fortified by this global recognition. 🌱 🎙️ Kiran Mazumdar-Shaw, Founder & Managing Trustee of Biocon Foundation, expressed immense pride in this achievement, highlighting the collaborative efforts of dedicated experts. Dr. Anupama Shetty, Mission Director of Biocon Foundation, emphasized the impact of these guidelines on combating oral cancer, especially in regions with limited healthcare access. 🌟 📈 These guidelines not only optimize treatment outcomes but also pave the way for improved success rates for HNC patients, offering hope and resilience in the fight against cancer. Let's continue to support initiatives like OCTF and Biocon Foundation in their noble endeavor to make a positive impact on cancer management globally! 💖 #cancerawareness #globalhealth #healthcareimpact #OCTF #clinicalpractice #CancerGuidelines Biocon Biocon Foundation - India Biocon Academy OCTF Official Oral Cancer Institute Dr Anupama Shetty Kiran Mazumdar Shaw Biocon Biologics Somesh Menon Shrishti Rao Ruchika Kumar Kuhu K Shweta Singh Sonal Dutta Arya Ameshi Ayush Kumar Patel Nancy Johri https://lnkd.in/gGg99cfc

Thirty years ago, kidney cancer was viewed as a single disease. There was no effective therapy for its advanced stages, resulting in 80 percent of patients with advanced kidney cancer dying within two years. In the early 1980s, William Marston Linehan and Berton Zbar initiated research on patients with sporadic kidney cancer, aiming to identify kidney cancer genes to lay the groundwork for targeted therapy development. The team discovered a chromosome 3 abnormality in these tumor types, suggesting it could be a sign of kidney cancer genes. Throughout years of Dr. Linehan's research, working with patients and involving their families, he discovered that there are various types of kidney cancer, each of which has unique genetic characteristics that respond to different therapy approaches. This discovery was a turning point in treating this deadly disease. Dr. Linehan and his team of researchers identified six genes for kidney cancer and five new inherited kidney diseases, defining the clinical features and surgical and medical treatments for these carcinomas. Dr. Linehan also established the foundation for targeted therapies for both hereditary and non-hereditary forms of kidney cancer. To date, researchers have managed to identify a total of 16 different genes that cause kidney cancer and a minimum of 13 distinct types of hereditary kidney cancer. Kidney Cancer Awareness Month shines a light on the incredible journey from early research to today's advanced treatments. As we reflect on the progress made, we also recognize the ongoing need for research and innovation in battling this disease. #KidneyCancerAwarenessMonth #Oncology #OncologyCompass

REHABILITATION NEEDS AND PERSPECTIVES IN LONG-TERM LUNG CANCER SURVIVORS S. Carnio, F. Tabbò, M.V. Pacchiana Parravicini, L. Buffoni An upadated review on JCR today! Lung cancer still remains the first cause of global cancer mortality but the advent of new therapeutic strategies is profoundly changing its prognosis. New survival data announce a significant increase in lung cancer survivors in the next decades. This population may have sequelae related to treatments or chronic side effects of ongoing therapies with remarkable repercussions on their quality of life. In this context, there will be different groups of lung cancer survivors with different demands and limitations. Therefore, it becomes relevant to properly identify their needs in order to design appropriate rehabilitation programs. Multidisciplinary work is essential in order to answer to physical, mental and social needs of this new group of survivors. We at JCR are delighted to share with you the paper and kindly ask to circulate this news amongst collaborators, colleagues and friends. The paper is available at https://lnkd.in/dzy7geab

Sarcoma Awareness Month strives to raise awareness about this rare and aggressive form of cancer each year during July. Although this month is now over, the impact of sarcoma continues to present significant unmet need in terms of research, diagnosis, and treatment all year-round, as this disease involves various cancer subtypes arising from connective tissues including bones and different soft tissues. Most of the treatment options currently available for sarcoma patients rely on conventional therapies such as chemotherapy. Nevertheless, this challenging disease merits further attention, specialized expertise and comprehensive understanding of different types of soft tissue sarcoma to determine the most effective treatment approach. Sarcoma requires its own unique and more innovative treatment with increased emphasis on #precisionmedicine! We are grateful and take pride to be working with Italiano Antoine, a prominent figure in oncology, a valuable member of our Scientific Advisory Board and our leading partner in the RHU CONDOR Program against Sarcoma, who has tirelessly devoted himself to addressing this unmet need. Professor Italiano's unwavering commitment to advancing sarcoma research has been pivotal in identifying novel treatment approaches and fostering collaborations. His remarkable work and contribution have transformed the understanding of this rare type of cancer. As we strive to develop precision medicine-enabled #immunotherapies at Domain Therapeutics in order to make a difference in the lives of cancer patients including those affected by sarcoma, we are privileged to have Professor Italiano's expertise and passion driving us forward. His unwavering determination to push the boundaries of science, coupled with his compassion for patients, inspires us in our fight against sarcoma and other cancers. With the guidance of such distinguished experts, we embrace hope and we are committed to a future where sarcoma is no longer a difficult adversary. Together we can make a difference! #immunooncology #drugdevelopment #cancerresearch #clinicalresearch

The time that passes from suspected cancer to diagnosis is often fragmented, with long waits and lack of coordination. This can lead to delays in diagnosis, and patients feeling added stress.   On this #WorldCancerResearchDay, check out this research article in Current Oncology MDPI from KTP scientists Drs. Tina Fahim, Sharon Straus, Canadian Partnership Against Cancer & team.   The research team explored barriers and facilitators to implementing and sustaining projects across Canada which aim to improve early cancer diagnosis.   The impact that the COVID-19 pandemic has had on cancer care and patient outcomes is not fully known, however, early studies show significant reductions in access and use of cancer screening and early diagnosis initiatives in Canada. Decreases in primary care visits, hospital visits, and screening rates can potentially impact patient outcomes. As the health care system aims to return to normal, it is crucial that early cancer diagnosis initiatives are improved, in order to provide care to individuals with suspected cancers. Understanding the barriers and facilitators to implementation and sustainability of early cancer diagnosis initiatives is a necessary first step in this process.   Read on to learn more about the challenges and opportunities that were uncovered (link to article in comments).

One thing we all share is the hope for a future where cancer is no longer a life-threatening disease. Ever wondered who's at the forefront shaping this future? Enter the Institute of Cancer Research ICR. The ICR is not just a bystander in cancer treatment's future; it's the driving force. Striving towards outsmarting cancer, ICR's groundbreaking research, strategic collaborations, and dedication to diversity and responsibility are steering the course of cancer treatment. Success stories from the ICR labs are already changing lives. Case in point, capivasertib - a targeted drug developed by ICR and AstraZeneca - now offers a ray of hope to those battling advanced breast cancer. Similarly, abiraterone, an ICR innovation from a decade ago, continues to provide a lifeline to patients with advanced prostate cancer. But it's not just about developing new treatments. ICR is revolutionizing the approach to cancer research. Collaborations with industry partners and research institutions are accelerating progress in the field as they pool resources, knowledge, and expertise. Their commitment to equity, too, stands out. ICR's research on prostate cancer in men of African ancestry is a leap towards more equitable testing strategies and personalized treatment plans. Bolstered by a spirit of philanthropy and community engagement, the ICR's pursuit is relentless. Each act of generosity brings us closer to a future where cancer doesn't hold the fear it does today. Every stride the ICR makes in its pursuit of outsmarting cancer takes us all a step closer to a future where cancer is history. Let's stand by them and take that step together. Are you with me? #CancerResearch #ICR #Innovation #Collaboration #EquityInHealthcare #OutsmartCancer #FutureOfCancerTreatment Read more on our blog: https://lnkd.in/exgMJWaH

Last week saw the launch of 'C the Signs' Cancer prediction system across the South Liverpool area, a collaboration of 4 PCNs (SWAGGA, Childwall & Wavertree, Picton and iGPc). This initiative, led by SWAGGA's Clinical Lead for Cancer (who also holds leadership roles with Liverpool Place Cancer and Cheshire and Merseyside Cancer Alliance), represents a significant leap forward in early cancer detection. In under 30 seconds, ‘C the Signs’ can rapidly identify which cancers a patient is at risk of and recommend the most appropriate test or specialist to diagnose their cancer. Through a collaborative effort, all 16 GP Practices within the SWAGGA PCN Network have adopted 'C the Signs'. This innovative system boasts the potential to identify patients at the earliest and most treatable stages of the disease. With early detection crucial for improving cancer survival rates, 'C the Signs' holds the promise of making a real difference in people's lives. Using the latest technology, research and evidence, C the Signs enables healthcare providers to give their patients the best chance of surviving cancer and help tackle health inequalities.

In November, Ontada had the honor of being selected by the FDA to study the natural history of patients with rare cancers in U.S. community cancer practices. For this project, we'll evaluate the following for 10 select cancers: 🧬 Patient and clinical characteristics at diagnosis 🧬 Treatment patterns 🧬 Long-term clinical outcomes 🧬 Survival following the rare cancer diagnosis By embarking on this study, we'll gain a better understanding of patient care for these rare cancers, which may inform trial design and help in the development of future treatments. Learn more: https://lnkd.in/gvnayrVq #RareCancer #CommunityOncology

Today is #WorldCancerDay! Ovarian cancer symptoms often appear in the later stages of cancer development. They often are prevalent symptoms in many other diseases, so narrowing down the diagnosis to ovarian cancer can be very difficult. Check out this interview with Nafissa Ismail and Dr. Ben Tsang to learn more https://lnkd.in/dThe3nfC Institut de recherche LIFE Research Institute